{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,8,12]],"date-time":"2025-08-12T22:03:35Z","timestamp":1755036215048,"version":"3.37.3"},"reference-count":79,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2021,6,7]],"date-time":"2021-06-07T00:00:00Z","timestamp":1623024000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2021,6,7]],"date-time":"2021-06-07T00:00:00Z","timestamp":1623024000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Curr. Treat. Options in Oncol."],"published-print":{"date-parts":[[2021,7]]},"DOI":"10.1007\/s11864-021-00857-w","type":"journal-article","created":{"date-parts":[[2021,6,7]],"date-time":"2021-06-07T12:10:09Z","timestamp":1623067809000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["Novel Biological Insights and New Developments in Management of Burkitt Lymphoma and High-Grade B-Cell Lymphoma"],"prefix":"10.1007","volume":"22","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6815-0695","authenticated-orcid":false,"given":"Coen J.","family":"Lap","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Samah","family":"Nassereddine","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kieron","family":"Dunleavy","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2021,6,7]]},"reference":[{"issue":"9822","key":"857_CR1","doi-asserted-by":"publisher","first-page":"1234","DOI":"10.1016\/S0140-6736(11)61177-X","volume":"379","author":"EM Molyneux","year":"2012","unstructured":"Molyneux EM, Rochford R, Griffin B, et al. Burkitt\u2019s lymphoma. Lancet. 2012;379(9822):1234\u201344.","journal-title":"Lancet."},{"issue":"10","key":"857_CR2","doi-asserted-by":"publisher","first-page":"3009","DOI":"10.1182\/blood-2004-02-0405","volume":"104","author":"KA Blum","year":"2004","unstructured":"Blum KA, Lozanski G, Byrd JC. Adult Burkitt leukemia and lymphoma. Blood. 2004;104(10):3009\u201320.","journal-title":"Blood."},{"issue":"197","key":"857_CR3","doi-asserted-by":"publisher","first-page":"218","DOI":"10.1002\/bjs.18004619704","volume":"46","author":"D Burkitt","year":"1958","unstructured":"Burkitt D. A sarcoma involving the jaws in African children. Br J Surg. 1958;46(197):218\u201323.","journal-title":"Br J Surg"},{"issue":"12","key":"857_CR4","first-page":"1397","volume":"60","author":"G Brady","year":"2007","unstructured":"Brady G, MacArthur GJ, Farrell PJ. Epstein-Barr virus and Burkitt lymphoma. J Clin Pathol. 2007;60(12):1397\u2013402.","journal-title":"J Clin Pathol"},{"issue":"25","key":"857_CR5","doi-asserted-by":"publisher","first-page":"5600","DOI":"10.1182\/blood-2010-03-275917","volume":"116","author":"M Guech-Ongey","year":"2010","unstructured":"Guech-Ongey M, Simard EP, Anderson WF, et al. AIDS-related Burkitt lymphoma in the United States: what do age and CD4 lymphocyte patterns tell us about etiology and\/or biology? Blood. 2010;116(25):5600\u20134.","journal-title":"Blood."},{"issue":"24","key":"857_CR6","doi-asserted-by":"publisher","first-page":"7824","DOI":"10.1073\/pnas.79.24.7824","volume":"79","author":"R Dalla-Favera","year":"1982","unstructured":"Dalla-Favera R, Bregni M, Erikson J, Patterson D, Gallo RC, Croce CM. Human c-myc onc gene is located on the region of chromosome 8 that is translocated in Burkitt lymphoma cells. Proc Natl Acad Sci U S A. 1982;79(24):7824\u20137.","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"7418","key":"857_CR7","doi-asserted-by":"publisher","first-page":"116","DOI":"10.1038\/nature11378","volume":"490","author":"R Schmitz","year":"2012","unstructured":"Schmitz R, Young RM, Ceribelli M, et al. Burkitt lymphoma pathogenesis and therapeutic targets from structural and functional genomics. Nature. 2012;490(7418):116\u201320.","journal-title":"Nature."},{"issue":"1","key":"857_CR8","doi-asserted-by":"publisher","first-page":"1459","DOI":"10.1038\/s41467-019-08578-3","volume":"10","author":"C Lopez","year":"2019","unstructured":"\u2022 Lopez C, Kleinheinz K, Aukema SM, et al. Genomic and transcriptomic changes complement each other in the pathogenesis of sporadic Burkitt lymphoma. Nat Commun. 2019;10(1):1459 Whole genome and transcriptome sequencing of 39 cases of sporadic BL reveals the mutational landscape, structural variants and mutational processes that underly sporadic BL pathogenesis.","journal-title":"Nat Commun"},{"issue":"11","key":"857_CR9","doi-asserted-by":"publisher","first-page":"665","DOI":"10.1200\/JOP.18.00148","volume":"14","author":"K Dunleavy","year":"2018","unstructured":"Dunleavy K. Approach to the diagnosis and treatment of adult Burkitt\u2019s lymphoma. J Oncol Pract. 2018;14(11):665\u201371.","journal-title":"J Oncol Pract"},{"issue":"3","key":"857_CR10","doi-asserted-by":"publisher","first-page":"254","DOI":"10.1182\/blood-2018-04-844472","volume":"132","author":"S Gopal","year":"2018","unstructured":"Gopal S, Gross TG. How I treat Burkitt lymphoma in children, adolescents, and young adults in sub-Saharan Africa. Blood. 2018;132(3):254\u201363.","journal-title":"Blood."},{"issue":"4","key":"857_CR11","doi-asserted-by":"publisher","first-page":"587","DOI":"10.1016\/j.hoc.2019.04.001","volume":"33","author":"R Alsharif","year":"2019","unstructured":"Alsharif R, Dunleavy K. Burkitt lymphoma and other high-grade b-cell lymphomas with or without MYC, BCL2, and\/or BCL6 rearrangements. Hematol Oncol Clin North Am. 2019;33(4):587\u201396.","journal-title":"Hematol Oncol Clin North Am"},{"issue":"1","key":"857_CR12","first-page":"181","volume":"128","author":"LJ Picker","year":"1987","unstructured":"Picker LJ, Weiss LM, Medeiros LJ, Wood GS, Warnke RA. Immunophenotypic criteria for the diagnosis of non-Hodgkin\u2019s lymphoma. Am J Pathol. 1987;128(1):181\u2013201.","journal-title":"Am J Pathol"},{"key":"857_CR13","doi-asserted-by":"publisher","first-page":"506","DOI":"10.1182\/asheducation-2011.1.506","volume":"2011","author":"ES Jaffe","year":"2011","unstructured":"Jaffe ES, Pittaluga S. Aggressive B-cell lymphomas: a review of new and old entities in the WHO classification. Hematology Am Soc Hematol Educ Program. 2011;2011:506\u201314.","journal-title":"Hematology Am Soc Hematol Educ Program"},{"issue":"5","key":"857_CR14","doi-asserted-by":"publisher","first-page":"1092","DOI":"10.1182\/blood.V77.5.1092.1092","volume":"77","author":"A Neri","year":"1991","unstructured":"Neri A, Barriga F, Inghirami G, et al. Epstein-Barr virus infection precedes clonal expansion in Burkitt\u2019s and acquired immunodeficiency syndrome-associated lymphoma. Blood. 1991;77(5):1092\u20135.","journal-title":"Blood."},{"issue":"12","key":"857_CR15","doi-asserted-by":"publisher","first-page":"738","DOI":"10.1016\/S1470-2045(04)01650-X","volume":"5","author":"CA van den Bosch","year":"2004","unstructured":"van den Bosch CA. Is endemic Burkitt\u2019s lymphoma an alliance between three infections and a tumour promoter? Lancet Oncol. 2004;5(12):738\u201346.","journal-title":"Lancet Oncol"},{"issue":"6","key":"857_CR16","doi-asserted-by":"publisher","DOI":"10.1371\/journal.ppat.0030080","volume":"3","author":"A Chene","year":"2007","unstructured":"Chene A, Donati D, Guerreiro-Cacais AO, et al. A molecular link between malaria and Epstein-Barr virus reactivation. PLoS Pathog. 2007;3(6):e80.","journal-title":"PLoS Pathog"},{"issue":"10","key":"857_CR17","doi-asserted-by":"publisher","first-page":"801","DOI":"10.1038\/nri1201","volume":"3","author":"R Kuppers","year":"2003","unstructured":"Kuppers R. B cells under influence: transformation of B cells by Epstein-Barr virus. Nat Rev Immunol. 2003;3(10):801\u201312.","journal-title":"Nat Rev Immunol"},{"issue":"12","key":"857_CR18","doi-asserted-by":"publisher","first-page":"1313","DOI":"10.1182\/blood-2018-09-871418","volume":"133","author":"BM Grande","year":"2019","unstructured":"\u2022\u2022 Grande BM, Gerhard DS, Jiang A, et al. Genome-wide discovery of somatic coding and noncoding mutations in pediatric endemic and sporadic Burkitt lymphoma. Blood. 2019;133(12):1313\u201324 Whole genome and transcriptome sequencing of BL cases reveals that EBV status defines a specific BL phenotype, irrespective of geographic location, with particular molecular properties and distinct pathogenic mechanisms that could be targeted with small molecule inhibitors.","journal-title":"Blood"},{"key":"857_CR19","doi-asserted-by":"crossref","unstructured":"Gabay M, Li Y, Felsher DW. MYC activation is a hallmark of cancer initiation and maintenance. Cold Spring Harb Perspect Med. 2014;4(6).","DOI":"10.1101\/cshperspect.a014241"},{"issue":"1","key":"857_CR20","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1002\/ijc.2910170108","volume":"17","author":"L Zech","year":"1976","unstructured":"Zech L, Haglund U, Nilsson K, Klein G. Characteristic chromosomal abnormalities in biopsies and lymphoid-cell lines from patients with Burkitt and non-Burkitt lymphomas. Int J Cancer. 1976;17(1):47\u201356.","journal-title":"Int J Cancer"},{"issue":"36","key":"857_CR21","doi-asserted-by":"publisher","first-page":"38591","DOI":"10.18632\/oncotarget.5774","volume":"6","author":"Q Cai","year":"2015","unstructured":"Cai Q, Medeiros LJ, Xu X, Young KH. MYC-driven aggressive B-cell lymphomas: biology, entity, differential diagnosis and clinical management. Oncotarget. 2015;6(36):38591\u2013616.","journal-title":"Oncotarget."},{"issue":"24","key":"857_CR22","doi-asserted-by":"publisher","first-page":"3884","DOI":"10.1182\/blood-2013-05-498329","volume":"122","author":"G Ott","year":"2013","unstructured":"Ott G, Rosenwald A, Campo E. Understanding MYC-driven aggressive B-cell lymphomas: pathogenesis and classification. Blood. 2013;122(24):3884\u201391.","journal-title":"Blood."},{"issue":"9","key":"857_CR23","doi-asserted-by":"publisher","first-page":"2984","DOI":"10.1073\/pnas.83.9.2984","volume":"83","author":"PG Pelicci","year":"1986","unstructured":"Pelicci PG, Knowles DM 2nd, Magrath I, Dalla-Favera R. Chromosomal breakpoints and structural alterations of the c-myc locus differ in endemic and sporadic forms of Burkitt lymphoma. Proc Natl Acad Sci U S A. 1986;83(9):2984\u20138.","journal-title":"Proc Natl Acad Sci U S A"},{"key":"857_CR24","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1016\/j.coi.2016.12.002","volume":"45","author":"P Ramezani-Rad","year":"2017","unstructured":"Ramezani-Rad P, Rickert RC. Murine models of germinal center derived-lymphomas. Curr Opin Immunol. 2017;45:31\u20136.","journal-title":"Curr Opin Immunol"},{"issue":"3","key":"857_CR25","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1002\/gcc.10178","volume":"36","author":"S Janz","year":"2003","unstructured":"Janz S, Potter M, Rabkin CS. Lymphoma- and leukemia-associated chromosomal translocations in healthy individuals. Genes Chromosom Cancer. 2003;36(3):211\u201323.","journal-title":"Genes Chromosom Cancer"},{"issue":"9","key":"857_CR26","doi-asserted-by":"publisher","first-page":"962","DOI":"10.1182\/blood-2018-07-864025","volume":"133","author":"R Wagener","year":"2019","unstructured":"\u2022 Wagener R, Seufert J, Raimondi F, et al. The mutational landscape of Burkitt-like lymphoma with 11q aberration is distinct from that of Burkitt lymphoma. Blood. 2019;133(9):962\u20136 Describes the new WHO provisional entity of \u201cBurkitt-like lymphoma with 11q aberration\u201d and shows how the molecular landscape of this subtype differs from other forms of BL.","journal-title":"Blood"},{"issue":"2","key":"857_CR27","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1016\/j.ccr.2012.06.012","volume":"22","author":"S Sander","year":"2012","unstructured":"Sander S, Calado DP, Srinivasan L, et al. Synergy between PI3K signaling and MYC in Burkitt lymphomagenesis. Cancer Cell. 2012;22(2):167\u201379.","journal-title":"Cancer Cell"},{"issue":"3","key":"857_CR28","doi-asserted-by":"publisher","first-page":"573","DOI":"10.1016\/j.cell.2009.08.041","volume":"139","author":"L Srinivasan","year":"2009","unstructured":"Srinivasan L, Sasaki Y, Calado DP, et al. PI3 kinase signals BCR-dependent mature B cell survival. Cell. 2009;139(3):573\u201386.","journal-title":"Cell."},{"key":"857_CR29","doi-asserted-by":"crossref","unstructured":"Schmitz R, Ceribelli M, Pittaluga S, Wright G, Staudt LM. Oncogenic mechanisms in Burkitt lymphoma. Cold Spring Harb Perspect Med. 2014;4(2).","DOI":"10.1101\/cshperspect.a014282"},{"issue":"12","key":"857_CR30","doi-asserted-by":"publisher","first-page":"1321","DOI":"10.1038\/ng.2468","volume":"44","author":"C Love","year":"2012","unstructured":"Love C, Sun Z, Jima D, et al. The genetic landscape of mutations in Burkitt lymphoma. Nat Genet. 2012;44(12):1321\u20135.","journal-title":"Nat Genet"},{"issue":"20","key":"857_CR31","doi-asserted-by":"publisher","first-page":"2375","DOI":"10.1182\/blood-2016-01-643569","volume":"127","author":"SH Swerdlow","year":"2016","unstructured":"Swerdlow SH, Campo E, Pileri SA, et al. The 2016 revision of the World Health Organization classification of lymphoid neoplasms. Blood. 2016;127(20):2375\u201390.","journal-title":"Blood."},{"issue":"8","key":"857_CR32","doi-asserted-by":"publisher","first-page":"1187","DOI":"10.1182\/blood-2013-06-507996","volume":"123","author":"I Salaverria","year":"2014","unstructured":"Salaverria I, Martin-Guerrero I, Wagener R, et al. A recurrent 11q aberration pattern characterizes a subset of MYC-negative high-grade B-cell lymphomas resembling Burkitt lymphoma. Blood. 2014;123(8):1187\u201398.","journal-title":"Blood."},{"issue":"7","key":"857_CR33","doi-asserted-by":"publisher","first-page":"e275","DOI":"10.3324\/haematol.2015.124305","volume":"100","author":"JF Ferreiro","year":"2015","unstructured":"Ferreiro JF, Morscio J, Dierickx D, et al. Post-transplant molecularly defined Burkitt lymphomas are frequently MYC-negative and characterized by the 11q-gain\/loss pattern. Haematologica. 2015;100(7):e275\u20139.","journal-title":"Haematologica."},{"issue":"3","key":"857_CR34","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1016\/j.cancergen.2015.12.005","volume":"209","author":"V Havelange","year":"2016","unstructured":"Havelange V, Ameye G, Theate I, et al. The peculiar 11q-gain\/loss aberration reported in a subset of MYC-negative high-grade B-cell lymphomas can also occur in a MYC-rearranged lymphoma. Cancer Gene Ther. 2016;209(3):117\u20138.","journal-title":"Cancer Gene Ther"},{"issue":"5","key":"857_CR35","doi-asserted-by":"publisher","first-page":"590","DOI":"10.1182\/blood-2017-04-737320","volume":"130","author":"JW Friedberg","year":"2017","unstructured":"Friedberg JW. How I treat double-hit lymphoma. Blood. 2017;130(5):590\u20136.","journal-title":"Blood."},{"issue":"4","key":"857_CR36","doi-asserted-by":"publisher","first-page":"777","DOI":"10.1038\/leu.2008.344","volume":"23","author":"N Niitsu","year":"2009","unstructured":"Niitsu N, Okamoto M, Miura I, Hirano M. Clinical features and prognosis of de novo diffuse large B-cell lymphoma with t(14;18) and 8q24\/c-MYC translocations. Leukemia. 2009;23(4):777\u201383.","journal-title":"Leukemia."},{"issue":"4","key":"857_CR37","doi-asserted-by":"publisher","first-page":"631","DOI":"10.1111\/bjh.14282","volume":"175","author":"DJ Landsburg","year":"2016","unstructured":"Landsburg DJ, Falkiewicz MK, Petrich AM, et al. Sole rearrangement but not amplification of MYC is associated with a poor prognosis in patients with diffuse large B cell lymphoma and B cell lymphoma unclassifiable. Br J Haematol. 2016;175(4):631\u201340.","journal-title":"Br J Haematol"},{"issue":"7","key":"857_CR38","doi-asserted-by":"publisher","first-page":"1540","DOI":"10.1093\/annonc\/mdx128","volume":"28","author":"A Kuhnl","year":"2017","unstructured":"Kuhnl A, Cunningham D, Counsell N, et al. Outcome of elderly patients with diffuse large B-cell lymphoma treated with R-CHOP: results from the UK NCRI R-CHOP14v21 trial with combined analysis of molecular characteristics with the DSHNHL RICOVER-60 trial. Annals of oncology: official journal of the European Society for Medical Oncology. 2017;28(7):1540\u20136.","journal-title":"Annals of oncology: official journal of the European Society for Medical Oncology"},{"issue":"35","key":"857_CR39","doi-asserted-by":"publisher","first-page":"3359","DOI":"10.1200\/JCO.19.00743","volume":"37","author":"A Rosenwald","year":"2019","unstructured":"\u2022 Rosenwald A, Bens S, Advani R, et al. Prognostic significance of MYC rearrangement and translocation partner in diffuse large b-cell lymphoma: a study by the Lunenburg Lymphoma Biomarker Consortium. J Clin Oncol. 2019;37(35):3359\u201368 Cohort study validating the negative prognostic impact of a MYC-rearrangement in DLBCL, especially when MYC is translocated to an IG partner.","journal-title":"J Clin Oncol"},{"issue":"6","key":"857_CR40","doi-asserted-by":"publisher","first-page":"744","DOI":"10.1111\/j.1365-2141.2011.09013.x","volume":"156","author":"I Magrath","year":"2012","unstructured":"Magrath I. Epidemiology: clues to the pathogenesis of Burkitt lymphoma. Br J Haematol. 2012;156(6):744\u201356.","journal-title":"Br J Haematol"},{"issue":"14","key":"857_CR41","doi-asserted-by":"publisher","first-page":"3245","DOI":"10.1182\/blood-2011-08-373738","volume":"119","author":"K Dunleavy","year":"2012","unstructured":"Dunleavy K, Wilson WH. How I treat HIV-associated lymphoma. Blood. 2012;119(14):3245\u201355.","journal-title":"Blood."},{"issue":"23","key":"857_CR42","doi-asserted-by":"publisher","first-page":"2431","DOI":"10.1056\/NEJMoa055759","volume":"354","author":"SS Dave","year":"2006","unstructured":"Dave SS, Fu K, Wright GW, et al. Molecular diagnosis of Burkitt\u2019s lymphoma. N Engl J Med. 2006;354(23):2431\u201342.","journal-title":"N Engl J Med"},{"issue":"7","key":"857_CR43","doi-asserted-by":"publisher","first-page":"1494","DOI":"10.1002\/ijc.30576","volume":"140","author":"F Mukhtar","year":"2017","unstructured":"Mukhtar F, Boffetta P, Risch HA, et al. Survival predictors of Burkitt\u2019s lymphoma in children, adults and elderly in the United States during 2000-2013. Int J Cancer. 2017;140(7):1494\u2013502.","journal-title":"Int J Cancer"},{"issue":"22","key":"857_CR44","first-page":"5810","volume":"47","author":"VT De Vita","year":"1987","unstructured":"De Vita VT, Jr., Hubbard SM, Longo DL. The chemotherapy of lymphomas: looking back, moving forward--the Richard and Hinda Rosenthal Foundation award lecture. Cancer Res. 1987;47(22):5810\u201324.","journal-title":"Cancer Res"},{"issue":"6","key":"857_CR45","doi-asserted-by":"publisher","first-page":"941","DOI":"10.1200\/JCO.1991.9.6.941","volume":"9","author":"ML McMaster","year":"1991","unstructured":"McMaster ML, Greer JP, Greco FA, Johnson DH, Wolff SN, Hainsworth JD. Effective treatment of small-noncleaved-cell lymphoma with high-intensity, brief-duration chemotherapy. J Clin Oncol. 1991;9(6):941\u20136.","journal-title":"J Clin Oncol"},{"issue":"4","key":"857_CR46","doi-asserted-by":"publisher","first-page":"369","DOI":"10.1182\/blood-2018-02-778480","volume":"132","author":"K Dunleavy","year":"2018","unstructured":"Dunleavy K, Gross TG. Management of aggressive B-cell NHLs in the AYA population: an adult vs pediatric perspective. Blood. 2018;132(4):369\u201375.","journal-title":"Blood."},{"issue":"3","key":"857_CR47","doi-asserted-by":"publisher","first-page":"925","DOI":"10.1200\/JCO.1996.14.3.925","volume":"14","author":"I Magrath","year":"1996","unstructured":"Magrath I, Adde M, Shad A, et al. Adults and children with small non-cleaved-cell lymphoma have a similar excellent outcome when treated with the same chemotherapy regimen. J Clin Oncol. 1996;14(3):925\u201334.","journal-title":"J Clin Oncol"},{"issue":"8","key":"857_CR48","doi-asserted-by":"publisher","first-page":"1264","DOI":"10.1093\/annonc\/mdf253","volume":"13","author":"GM Mead","year":"2002","unstructured":"Mead GM, Sydes MR, Walewski J, et al. An international evaluation of CODOX-M and CODOX-M alternating with IVAC in adult Burkitt\u2019s lymphoma: results of United Kingdom Lymphoma Group LY06 study. Ann Oncol. 2002;13(8):1264\u201374.","journal-title":"Ann Oncol"},{"issue":"6","key":"857_CR49","doi-asserted-by":"publisher","first-page":"2248","DOI":"10.1182\/blood-2008-03-145128","volume":"112","author":"GM Mead","year":"2008","unstructured":"Mead GM, Barrans SL, Qian W, et al. A prospective clinicopathologic study of dose-modified CODOX-M\/IVAC in patients with sporadic Burkitt lymphoma defined using cytogenetic and immunophenotypic criteria (MRC\/NCRI LY10 trial). Blood. 2008;112(6):2248\u201360.","journal-title":"Blood."},{"issue":"4","key":"857_CR50","doi-asserted-by":"publisher","first-page":"761","DOI":"10.1080\/1042819031000141301","volume":"45","author":"A Lacasce","year":"2004","unstructured":"Lacasce A, Howard O, Lib S, et al. Modified magrath regimens for adults with Burkitt and Burkitt-like lymphomas: preserved efficacy with decreased toxicity. Leuk Lymphoma. 2004;45(4):761\u20137.","journal-title":"Leuk Lymphoma"},{"issue":"6","key":"857_CR51","doi-asserted-by":"publisher","first-page":"1196","DOI":"10.1002\/cncr.11628","volume":"98","author":"ES Wang","year":"2003","unstructured":"Wang ES, Straus DJ, Teruya-Feldstein J, et al. Intensive chemotherapy with cyclophosphamide, doxorubicin, high-dose methotrexate\/ifosfamide, etoposide, and high-dose cytarabine (CODOX-M\/IVAC) for human immunodeficiency virus-associated Burkitt lymphoma. Cancer. 2003;98(6):1196\u2013205.","journal-title":"Cancer."},{"issue":"8","key":"857_CR52","doi-asserted-by":"publisher","first-page":"1859","DOI":"10.1093\/annonc\/mdq677","volume":"22","author":"JA Barnes","year":"2011","unstructured":"Barnes JA, Lacasce AS, Feng Y, et al. Evaluation of the addition of rituximab to CODOX-M\/IVAC for Burkitt\u2019s lymphoma: a retrospective analysis. Ann Oncol. 2011;22(8):1859\u201364.","journal-title":"Ann Oncol"},{"issue":"2","key":"857_CR53","doi-asserted-by":"publisher","first-page":"160","DOI":"10.1182\/blood-2015-01-623900","volume":"126","author":"A Noy","year":"2015","unstructured":"Noy A, Lee JY, Cesarman E, et al. AMC 048: modified CODOX-M\/IVAC-rituximab is safe and effective for HIV-associated Burkitt lymphoma. Blood. 2015;126(2):160\u20136.","journal-title":"Blood."},{"issue":"2","key":"857_CR54","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1111\/j.1365-2141.2010.08447.x","volume":"152","author":"SG Mohamedbhai","year":"2011","unstructured":"Mohamedbhai SG, Sibson K, Marafioti T, et al. Rituximab in combination with CODOX-M\/IVAC: a retrospective analysis of 23 cases of non-HIV related B-cell non-Hodgkin lymphoma with proliferation index >95%. Br J Haematol. 2011;152(2):175\u201381.","journal-title":"Br J Haematol"},{"issue":"23","key":"857_CR55","doi-asserted-by":"publisher","first-page":"2207","DOI":"10.1056\/NEJMoa1915315","volume":"382","author":"V Minard-Colin","year":"2020","unstructured":"Minard-Colin V, Auperin A, Pillon M, et al. Rituximab for high-risk, mature B-cell non-Hodgkin\u2019s lymphoma in children. N Engl J Med. 2020;382(23):2207\u201319.","journal-title":"N Engl J Med"},{"issue":"8","key":"857_CR56","doi-asserted-by":"publisher","first-page":"2461","DOI":"10.1200\/JCO.1999.17.8.2461","volume":"17","author":"DA Thomas","year":"1999","unstructured":"Thomas DA, Cortes J, O'Brien S, et al. Hyper-CVAD program in Burkitt\u2019s-type adult acute lymphoblastic leukemia. J Clin Oncol. 1999;17(8):2461\u201370.","journal-title":"J Clin Oncol"},{"issue":"7","key":"857_CR57","doi-asserted-by":"publisher","first-page":"1569","DOI":"10.1002\/cncr.21776","volume":"106","author":"DA Thomas","year":"2006","unstructured":"Thomas DA, Faderl S, O'Brien S, et al. Chemoimmunotherapy with hyper-CVAD plus rituximab for the treatment of adult Burkitt and Burkitt-type lymphoma or acute lymphoblastic leukemia. Cancer. 2006;106(7):1569\u201380.","journal-title":"Cancer."},{"issue":"7","key":"857_CR58","doi-asserted-by":"publisher","first-page":"1438","DOI":"10.1002\/cncr.20143","volume":"100","author":"DA Rizzieri","year":"2004","unstructured":"Rizzieri DA, Johnson JL, Niedzwiecki D, et al. Intensive chemotherapy with and without cranial radiation for Burkitt leukemia and lymphoma: final results of Cancer and Leukemia Group B Study 9251. Cancer. 2004;100(7):1438\u201348.","journal-title":"Cancer."},{"issue":"1","key":"857_CR59","doi-asserted-by":"publisher","first-page":"102","DOI":"10.1111\/bjh.12736","volume":"165","author":"DA Rizzieri","year":"2014","unstructured":"Rizzieri DA, Johnson JL, Byrd JC, et al. Improved efficacy using rituximab and brief duration, high intensity chemotherapy with filgrastim support for Burkitt or aggressive lymphomas: cancer and Leukemia Group B study 10 002. Br J Haematol. 2014;165(1):102\u201311.","journal-title":"Br J Haematol"},{"issue":"12","key":"857_CR60","doi-asserted-by":"publisher","first-page":"1928","DOI":"10.1093\/annonc\/mdi403","volume":"16","author":"M Divine","year":"2005","unstructured":"Divine M, Casassus P, Koscielny S, et al. Burkitt lymphoma in adults: a prospective study of 72 patients treated with an adapted pediatric LMB protocol. Ann Oncol. 2005;16(12):1928\u201335.","journal-title":"Ann Oncol"},{"issue":"10036","key":"857_CR61","doi-asserted-by":"publisher","first-page":"2402","DOI":"10.1016\/S0140-6736(15)01317-3","volume":"387","author":"V Ribrag","year":"2016","unstructured":"Ribrag V, Koscielny S, Bosq J, et al. Rituximab and dose-dense chemotherapy for adults with Burkitt\u2019s lymphoma: a randomised, controlled, open-label, phase 3 trial. Lancet. 2016;387(10036):2402\u201311.","journal-title":"Lancet."},{"issue":"26","key":"857_CR62","doi-asserted-by":"publisher","first-page":"3870","DOI":"10.1182\/blood-2014-03-563627","volume":"124","author":"D Hoelzer","year":"2014","unstructured":"Hoelzer D, Walewski J, Dohner H, et al. Improved outcome of adult Burkitt lymphoma\/leukemia with rituximab and chemotherapy: report of a large prospective multicenter trial. Blood. 2014;124(26):3870\u20139.","journal-title":"Blood."},{"issue":"20","key":"857_CR63","doi-asserted-by":"publisher","first-page":"1915","DOI":"10.1056\/NEJMoa1308392","volume":"369","author":"K Dunleavy","year":"2013","unstructured":"Dunleavy K, Pittaluga S, Shovlin M, et al. Low-intensity therapy in adults with Burkitt\u2019s lymphoma. N Engl J Med. 2013;369(20):1915\u201325.","journal-title":"N Engl J Med"},{"key":"857_CR64","doi-asserted-by":"crossref","unstructured":"Dunleavy K, Roschewski M, Abramson J, et al. Risk-adapted therapy in adults with burkitt lymphoma: updated results of a Multi-Center Prospective Phase II Study of DA-EPOCH-R. Haematological Oncology. 2017;35(Proc Lugano Lymphoma Meeting 2017).","DOI":"10.1002\/hon.2437_122"},{"issue":"22","key":"857_CR65","doi-asserted-by":"publisher","first-page":"2519","DOI":"10.1200\/JCO.20.00303","volume":"38","author":"M Roschewski","year":"2020","unstructured":"\u2022\u2022 Roschewski M, Dunleavy K, Abramson JS, et al. Multicenter study of risk-adapted therapy with dose-adjusted EPOCH-R in adults with untreated Burkitt lymphoma. J Clin Oncol. 2020;38(22):2519\u201329 Phase II study showing that risk-adapted, dose-adjusted EPOCH-R is effective in adult BL, regardless of age or HIV status, and is well tolerated.","journal-title":"J Clin Oncol"},{"key":"857_CR66","unstructured":"Evens AM, Danilov AV, Jagadeesh D, et al. Burkitt lymphoma in the Modern Era: real world outcomes and prognostication across 30 US cancer centers. Blood. 2020."},{"issue":"9","key":"857_CR67","doi-asserted-by":"publisher","first-page":"2465","DOI":"10.1200\/JCO.1996.14.9.2465","volume":"14","author":"JW Sweetenham","year":"1996","unstructured":"Sweetenham JW, Pearce R, Taghipour G, Blaise D, Gisselbrecht C, Goldstone AH. Adult Burkitt\u2019s and Burkitt-like non-Hodgkin\u2019s lymphoma--outcome for patients treated with high-dose therapy and autologous stem-cell transplantation in first remission or at relapse: results from the European Group for Blood and Marrow Transplantation. J Clin Oncol. 1996;14(9):2465\u201372.","journal-title":"J Clin Oncol"},{"issue":"14","key":"857_CR68","doi-asserted-by":"publisher","first-page":"1078","DOI":"10.1182\/blood.2020005329","volume":"135","author":"A Simkins","year":"2020","unstructured":"Simkins A, Dunleavy K. Tackling Burkitt when it\u2019s back. Blood. 2020;135(14):1078\u201380.","journal-title":"Blood."},{"issue":"6","key":"857_CR69","doi-asserted-by":"publisher","first-page":"E114","DOI":"10.1002\/ajh.24720","volume":"92","author":"NJ Short","year":"2017","unstructured":"Short NJ, Kantarjian HM, Ko H, et al. Outcomes of adults with relapsed or refractory Burkitt and high-grade B-cell leukemia\/lymphoma. Am J Hematol. 2017;92(6):E114\u20137.","journal-title":"Am J Hematol"},{"issue":"17","key":"857_CR70","doi-asserted-by":"publisher","first-page":"3533","DOI":"10.1182\/blood-2009-05-220095","volume":"114","author":"KJ Savage","year":"2009","unstructured":"Savage KJ, Johnson NA, Ben-Neriah S, et al. MYC gene rearrangements are associated with a poor prognosis in diffuse large B-cell lymphoma patients treated with R-CHOP chemotherapy. Blood. 2009;114(17):3533\u20137.","journal-title":"Blood."},{"issue":"1","key":"857_CR71","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1182\/asheducation-2014.1.107","volume":"2014","author":"K Dunleavy","year":"2014","unstructured":"Dunleavy K. Double-hit lymphomas: current paradigms and novel treatment approaches. Hematology Am Soc Hematol Educ Program. 2014;2014(1):107\u201312.","journal-title":"Hematology Am Soc Hematol Educ Program"},{"issue":"12","key":"857_CR72","doi-asserted-by":"publisher","first-page":"e609","DOI":"10.1016\/S2352-3026(18)30177-7","volume":"5","author":"K Dunleavy","year":"2018","unstructured":"\u2022\u2022 Dunleavy K, Fanale MA, Abramson JS, et al. Dose-adjusted EPOCH-R (etoposide, prednisone, vincristine, cyclophosphamide, doxorubicin, and rituximab) in untreated aggressive diffuse large B-cell lymphoma with MYC rearrangement: a prospective, multicentre, single-arm phase 2 study. Lancet Haematol. 2018;5(12):e609\u201317 Phase II study showing that dose-adjusted EPOCH-R is able to produce durable remissions in patients with MYC-rearranged aggressive B-cell lymphoma and should be considered for the treatment of these diseases.","journal-title":"Lancet Haematol"},{"issue":"12","key":"857_CR73","doi-asserted-by":"publisher","first-page":"2805","DOI":"10.3324\/haematol.2019.238162","volume":"105","author":"MED Chamuleau","year":"2020","unstructured":"Chamuleau MED, Burggraaf CN, Nijland M, et al. Treatment of patients with MYC rearrangement positive large B-cell lymphoma with R-CHOP plus lenalidomide: results of a multi-center HOVON phase II trial. Haematol. 2020;105(12):2805\u201312.","journal-title":"Haematol."},{"issue":"1","key":"857_CR74","doi-asserted-by":"publisher","first-page":"12046","DOI":"10.1038\/s41598-018-30509-3","volume":"8","author":"K Tomska","year":"2018","unstructured":"\u2022 Tomska K, Kurilov R, Lee KS, et al. Drug-based perturbation screen uncovers synergistic drug combinations in Burkitt lymphoma. Sci Rep. 2018;8(1):12046 Study that describes drug response profiling in BL revealing not only potential synergistic combinations but also that targeting CDK and BET could provide a novel vulnerability.","journal-title":"Sci Rep"},{"issue":"10","key":"857_CR75","doi-asserted-by":"publisher","first-page":"2761","DOI":"10.1158\/0008-5472.CAN-18-1545","volume":"79","author":"T Shorstova","year":"2019","unstructured":"Shorstova T, Marques M, Su J, et al. SWI\/SNF-compromised cancers are susceptible to bromodomain inhibitors. Cancer Res. 2019;79(10):2761\u201374.","journal-title":"Cancer Res"},{"issue":"6","key":"857_CR76","doi-asserted-by":"publisher","first-page":"904","DOI":"10.1016\/j.cell.2011.08.017","volume":"146","author":"JE Delmore","year":"2011","unstructured":"Delmore JE, Issa GC, Lemieux ME, et al. BET bromodomain inhibition as a therapeutic strategy to target c-myc. Cell. 2011;146(6):904\u201317.","journal-title":"Cell."},{"issue":"24","key":"857_CR77","doi-asserted-by":"publisher","first-page":"6185","DOI":"10.1158\/1078-0432.CCR-18-0426","volume":"24","author":"G Enblad","year":"2018","unstructured":"Enblad G, Karlsson H, Gammelgard G, et al. A Phase I\/IIa Trial using CD19-targeted third-generation CAR T cells for lymphoma and leukemia. Clin Cancer Res. 2018;24(24):6185\u201394.","journal-title":"Clin Cancer Res"},{"issue":"12","key":"857_CR78","doi-asserted-by":"publisher","first-page":"1583","DOI":"10.1038\/s41409-018-0235-0","volume":"53","author":"A Avigdor","year":"2018","unstructured":"\u2022 Avigdor A, Shouval R, Jacoby E, et al. CAR T cells induce a complete response in refractory Burkitt Lymphoma. Bone Marrow Transplant. 2018;53(12):1583\u20135 Case-report of a patient with relapsed BL that was treated with salvage CAR T-cell therapy resulting in a deep response.","journal-title":"Bone Marrow Transplant"},{"issue":"26","key":"857_CR79","doi-asserted-by":"publisher","first-page":"2531","DOI":"10.1056\/NEJMoa1707447","volume":"377","author":"SS Neelapu","year":"2017","unstructured":"Neelapu SS, Locke FL, Bartlett NL, et al. Axicabtagene ciloleucel CAR T-Cell therapy in refractory large B-cell lymphoma. N Engl J Med. 2017;377(26):2531\u201344.","journal-title":"N Engl J Med"}],"container-title":["Current Treatment Options in Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11864-021-00857-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11864-021-00857-w\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11864-021-00857-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,2,3]],"date-time":"2023-02-03T16:37:38Z","timestamp":1675442258000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11864-021-00857-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,6,7]]},"references-count":79,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2021,7]]}},"alternative-id":["857"],"URL":"https:\/\/doi.org\/10.1007\/s11864-021-00857-w","relation":{},"ISSN":["1527-2729","1534-6277"],"issn-type":[{"type":"print","value":"1527-2729"},{"type":"electronic","value":"1534-6277"}],"subject":[],"published":{"date-parts":[[2021,6,7]]},"assertion":[{"value":"31 March 2021","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 June 2021","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with Ethical Standards"}},{"value":"Coen J. Lap declares that he has no conflict of interest.Samah Nassereddine declares that she has no conflict of interest.Kieron Dunleavy has received compensation for service as a consultant from Daiichi Sankyo, Pharmacyclics, Amgen\/AbbVie, AstraZeneca, MorphoSys, Genmab, Genentech, and Janssen.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}}],"article-number":"60"}}